



# New Hampshire Medicaid Fee-for-Service (FFS) Program

## Prior Authorization Drug Approval Form

MACE - Wegovy

DATE OF MEDICATION REQUEST:     /     /

### SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

MEDICAID ID NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

DATE OF BIRTH:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

GENDER: ☐ Male ☐ Female

Drug Name

Strength

Dosing Directions

Length of Therapy

### SECTION II: PRESCRIBER INFORMATION

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SPECIALTY:

NPI NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PHONE NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FAX NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

### SECTION III: CLINICAL HISTORY

1. Does the patient have a diagnosis of Type 1 or Type 2 Diabetes Mellitus? ☐ Yes ☐ No

2. Has the patient failed to lose weight on a low-calorie diet (1,200 kcal/day for women, 1,600 kcal/day for men) **and** increased physical activity including strength training? ☐ Yes ☐ No

Explain if no: \_\_\_\_\_

3. Does the patient have a body mass index (BMI) of at least 27 kg/m<sup>2</sup>? ☐ Yes ☐ No

4. Patient's BMI: \_\_\_\_\_ Weight: \_\_\_\_\_ Height: \_\_\_\_\_ Date: \_\_\_\_\_

Phone: 1-866-675-7755

Fax: 1-888-603-7696

© 2021–2026 Prime Therapeutics Management LLC, a Prime Therapeutics LLC company

Revision Date: 01/01/2026





**New Hampshire Medicaid Fee-for-Service (FFS) Program**  
**Prior Authorization Drug Approval Form**  
MACE - Wegovy

**PATIENT LAST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**PATIENT FIRST NAME:**

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**SECTION III: CLINICAL HISTORY (*continued*)**

5. Does the patient have established cardiovascular disease? ☐ Yes ☐ No
6. Is the patient currently taking drugs for secondary prevention of major adverse cardiovascular events (MACE)?  
(Check all that apply.)
- ☐ Statin, ezetimibe, PCSK9 inhibitor, or combination \_\_\_\_\_
- ☐ Blood pressure medication (ACEI/ARB) \_\_\_\_\_
- ☐ Beta-blocker \_\_\_\_\_
- ☐ Anticoagulant or Antiplatelet therapy \_\_\_\_\_
7. Is the patient at risk for MACE? ☐ Yes ☐ No
8. Is there any additional information that would help in the decision-making process?  
If additional space is needed, please use a separate sheet.

**SECTION IV: RENEWAL**

1. Has the patient continued on a low-calorie diet (1,200 kcal/day for women, 1,600 kcal/day for men) **and** increased physical activity including strength training? ☐ Yes ☐ No
2. Has the patient continued the guideline-recommended measures for MACE prevention? ☐ Yes ☐ No  
List additional medications: \_\_\_\_\_
3. Has the patient experienced any treatment-restricting adverse effects? ☐ Yes ☐ No

**Baseline body weight:** \_\_\_\_\_ **Renewal body weight:** \_\_\_\_\_

**I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.**

**PRESCRIBER'S SIGNATURE:** \_\_\_\_\_ **DATE:** \_\_\_\_\_